​

ORIC Pharmaceuticals (ORIC) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ORIC Stock Forecast

ORIC Pharmaceuticals (ORIC) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $19.25, with a high of $25.00 and a low of $15.00. This represents a 146.16% increase from the last price of $7.82.

$5 $9 $13 $17 $21 $25 High: $25 Avg: $19.25 Low: $15 Last Closed Price: $7.82

ORIC Stock Rating

ORIC Pharmaceuticals stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

ORIC Price Target Upside V Benchmarks

TypeNameUpside
StockORIC Pharmaceuticals146.16%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts117
Avg Price Target$15.00$15.00$20.43
Last Closing Price$7.82$7.82$7.82
Upside/Downside91.82%91.82%161.25%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 262131--16
May, 262121--15
Apr, 262121--15
Mar, 262121--15
Feb, 262121--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 15, 2026Goldman Sachs$15.00$8.3479.86%91.82%
Feb 24, 2026Robert BurnsH.C. Wainwright$25.00$13.2788.39%219.69%
Feb 24, 2026Matthew BieglerOppenheimer$15.00$11.7128.10%91.82%
Jan 07, 2026Kelsey GoodwinPiper Sandler$22.00$8.14170.27%181.33%
Dec 08, 2025Wells Fargo$25.00$11.00127.27%219.69%
Nov 14, 2025H.C. Wainwright$23.00$12.7879.97%194.12%
Sep 04, 2025Brad CaninoGuggenheim$18.00$10.6069.81%130.18%
May 06, 2025Matthew BieglerOppenheimer$12.00$5.04138.10%53.45%
Sep 05, 2024Bradley CaninoStifel Nicolaus$20.00$9.48110.97%155.75%
Mar 21, 2024Robert BurnsH.C. Wainwright$21.00$14.5943.93%168.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 08, 2026H.C. WainwrightBuyBuyhold
May 22, 2026Cantor FitzgeraldOverweightOverweighthold
Mar 09, 2026Cantor FitzgeraldOverweightOverweighthold
Mar 09, 2026Wolfe ResearchNegativeNegativehold
Feb 24, 2026H.C. WainwrightBuyBuyhold
Feb 24, 2026CitigroupBuyBuyhold
Feb 24, 2026OppenheimerOutperformOutperformhold
Jan 07, 2026Piper SandlerOverweightinitialise
Dec 08, 2025Wells FargoOverweightOverweighthold
Nov 14, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.96$-1.83$-1.47---
Avg Forecast$-1.96$-1.86$-2.04$-2.12$-2.19$-1.58
High Forecast$-1.91$-1.84$-1.90$-1.47$-1.52$-1.58
Low Forecast$-2.02$-1.88$-2.20$-2.69$-3.04$-1.58
Surprise %--1.61%-27.94%---

Revenue Forecast

$15M $29M $43M $57M $71M $85M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$15.70M$15.15M$81.00M
High Forecast---$15.70M$15.15M$81.00M
Low Forecast---$15.70M$15.15M$81.00M
Surprise %------

Net Income Forecast

$-160M $-143M $-126M $-109M $-92M $-75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-100.70M$-127.85M$-129.47M---
Avg Forecast$-100.70M$-95.65M$-105.55M$-107.17M$-117.24M$-81.46M
High Forecast$-98.06M$-94.61M$-97.73M$-75.74M$-77.99M$-81.46M
Low Forecast$-103.74M$-96.69M$-113.37M$-138.61M$-156.49M$-81.46M
Surprise %-33.66%22.66%---

ORIC Forecast FAQ

Is ORIC Pharmaceuticals stock a buy?

ORIC Pharmaceuticals stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ORIC Pharmaceuticals is a favorable investment for most analysts.

What is ORIC Pharmaceuticals's price target?

ORIC Pharmaceuticals's price target, set by 10 Wall Street analysts, averages $19.25 over the next 12 months. The price target range spans from $15 at the low end to $25 at the high end, suggesting a potential 146.16% change from the previous closing price of $7.82.

How does ORIC Pharmaceuticals stock forecast compare to its benchmarks?

ORIC Pharmaceuticals's stock forecast shows a 146.16% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for ORIC Pharmaceuticals over the past three months?

  • June 2026: 12.50% Strong Buy, 81.25% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 13.33% Strong Buy, 80.00% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 13.33% Strong Buy, 80.00% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.

What is ORIC Pharmaceuticals’s EPS forecast?

ORIC Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.12, marking a 44.22% increase from the reported $-1.47 in 2025. Estimates for the following years are $-2.19 in 2027, and $-1.58 in 2028.

What is ORIC Pharmaceuticals’s revenue forecast?

ORIC Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $15.7M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $15.15M, and $81M for 2028.

What is ORIC Pharmaceuticals’s net income forecast?

ORIC Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-107M, representing a -17.22% decrease from the reported $-129M in 2025. Projections indicate $-117M in 2027, and $-81.464M in 2028.